A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI

Trial Profile

A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Odiparcil (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions
  • Acronyms iMProveS trial
  • Sponsors Inventiva Pharma
  • Most Recent Events

    • 13 Apr 2018 According to an Inventiva Pharma media release, results from this trial are expected in the first half of 2019.
    • 11 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Mar 2020.
    • 11 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top